|
Match
|
Document |
Document Title |
|
|
US20140294763 |
PEPTIDOMIMETIC PROTEASE INHIBITORS
The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors;... |
|
|
US20130058894 |
THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE
Disclosed are therapeutic protein-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. |
|
|
US20120064034 |
Peptidomimetic protease inhibitors
The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors;... |
|
|
US20110117057 |
NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses... |
|
|
US20090004135 |
MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a... |
|
|
US20080008682 |
Modulators of toll-like receptor 7
The present application provides for a compound of Formula I or II: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic... |
|
|
US20170065592 |
MODULATORS OF TOLL-LIKE RECEPTORS
Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such... |
|
|
US20160152687 |
ALBUMIN FUSION PROTEINS
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors... |
|
|
US20150343080 |
GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a... |
|
|
US20150118186 |
PYRAZOLE DERIVATIVES AS JAK INHIBITORS
New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy... |
|
|
US20150064118 |
LIPID DEPOT FORMULATIONS
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least... |
|
|
US20150056167 |
PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME
Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from... |
|
|
US20140294762 |
GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a... |
|
|
US20140065097 |
Immunotherapy
The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased... |
|
|
US20140056847 |
INHIBITORS OF SERINE PROTEASES
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers... |
|
|
US20130344138 |
METHODS OF TREATMENT FOR SOLID TUMORS
The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises... |
|
|
US20130315868 |
D-AMINO ACID COMPOUNDS FOR LIVER DISEASE
Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of... |
|
|
US20130177531 |
Inhibitors of Serine Proteases
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers... |
|
|
US20120258073 |
IMMUNOTHERAPY
The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased... |
|
|
US20110182857 |
Delivery of Drugs to Mucosal Surfaces
Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or... |
|
|
US20110171175 |
INHIBITORS OF SERINE PROTEASES
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers... |
|
|
US20110135605 |
METHODS AND PRODUCTS RELATED TO TREATMENT AND PREVENTION OF HEPATITIS C VIRUS INFECTION
The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy.... |
|
|
US20110086006 |
HCV NS3-NS4 Protease Resistance Mutants
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. |
|
|
US20110081315 |
NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions,... |
|
|
US20100003217 |
Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are... |
|
|
US20080292712 |
METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF BIOACTIVE MOLECULES
Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid... |
|
|
US20080253998 |
TREATMENT OF CANCER USING TLR3 AGONISTS
The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by... |
|
|
US20070274951 |
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but... |
|
|
US20060182716 |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more... |
|
|
US20060140907 |
Central airway administration for systemic delivery of therapeutics
The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic... |
|
|
US20050002916 |
Cytokine-expressing cellular vaccine combinations
The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the administration of the combination of a... |
|
|
US20150259431 |
COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors... |
|
|
US20150216938 |
COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS
Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV... |
|
|
US20150017124 |
MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment... |
|
|
US20140301976 |
NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore... |
|
|
US20130273005 |
METHODS FOR TREATING HCV
This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions. |
|
|
US20130259832 |
Combinations of Hepatitis C Virus Inhibitors
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising... |
|
|
US20120294831 |
USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS
The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating... |
|
|
US20120225033 |
Biodegradable Drug Delivery Composition
The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the... |
|
|
US20120195857 |
Hepatitis C Virus Inhibitors
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such... |
|
|
US20120177697 |
Excipients In Drug Delivery Vehicles
Injectable depot gel compositions and kits that provide an excipient for modulating a release rate and stabilizing beneficial agents are provided. Methods of administering and preparing such... |
|
|
US20110182982 |
LIPOSOME TREATMENT OF VIRAL INFECTIONS
One can treat a viral infection such as hepatitis B (HBV), hepatitis C(HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the... |
|
|
US20100291034 |
COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO
Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease... |
|
|
US20100260706 |
COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors... |
|
|
US20100119479 |
THERAPEUTIC ANTIVIRAL PEPTIDES
Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed. |
|
|
US20090285752 |
IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially... |
|
|
US20090269303 |
METHOD FOR TREATING OR PREVENTING CONDITIONS BY ELEVATION OF THE ADENOSINE LEVEL IN AN INDIVIDUAL
This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to the individual an effective amount of either i) recombinant protein CD73 or ii) a... |
|
|
US20090155209 |
NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment... |
|
|
US20080213219 |
Methods for treatment and management of macular degeneration using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically... |
|
|
US20070071721 |
METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29
IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on... |